I. Slowly growing organism; making them relatively resistant to antibiotics II. Mycobacterial cells...
-
Upload
brooke-watkins -
Category
Documents
-
view
223 -
download
0
Transcript of I. Slowly growing organism; making them relatively resistant to antibiotics II. Mycobacterial cells...
![Page 1: I. Slowly growing organism; making them relatively resistant to antibiotics II. Mycobacterial cells can also be dormant and thus completely resistant.](https://reader035.fdocuments.us/reader035/viewer/2022062216/56649d9c5503460f94a8515d/html5/thumbnails/1.jpg)
![Page 2: I. Slowly growing organism; making them relatively resistant to antibiotics II. Mycobacterial cells can also be dormant and thus completely resistant.](https://reader035.fdocuments.us/reader035/viewer/2022062216/56649d9c5503460f94a8515d/html5/thumbnails/2.jpg)
I. Slowly growing organism; making them relatively resistant to antibiotics
II. Mycobacterial cells can also be dormant and thus completely resistant to many drugs
III. Lipid rich mycobacterial cell wall is impermeable to many agents
IV. Substantial proportion of mycobacterial organism are intracellular, residing with macrophages and inaccessible to drugs
V. Notorious for their ability to develop resistance to any single drug
A. Characteristics
![Page 3: I. Slowly growing organism; making them relatively resistant to antibiotics II. Mycobacterial cells can also be dormant and thus completely resistant.](https://reader035.fdocuments.us/reader035/viewer/2022062216/56649d9c5503460f94a8515d/html5/thumbnails/3.jpg)
Drugs used in Tuberculosis
Drugs used in Atypical mycobacteria
Drugs used in Leprosy
B. Agents
![Page 4: I. Slowly growing organism; making them relatively resistant to antibiotics II. Mycobacterial cells can also be dormant and thus completely resistant.](https://reader035.fdocuments.us/reader035/viewer/2022062216/56649d9c5503460f94a8515d/html5/thumbnails/4.jpg)
Drugs used in Tuberculosis
![Page 5: I. Slowly growing organism; making them relatively resistant to antibiotics II. Mycobacterial cells can also be dormant and thus completely resistant.](https://reader035.fdocuments.us/reader035/viewer/2022062216/56649d9c5503460f94a8515d/html5/thumbnails/5.jpg)
First line Anti TB Drugs
![Page 6: I. Slowly growing organism; making them relatively resistant to antibiotics II. Mycobacterial cells can also be dormant and thus completely resistant.](https://reader035.fdocuments.us/reader035/viewer/2022062216/56649d9c5503460f94a8515d/html5/thumbnails/6.jpg)
1)Isoniazid2)Rifampin3)Pyrazinamide4)Ethambutol5)Streptomycin
![Page 7: I. Slowly growing organism; making them relatively resistant to antibiotics II. Mycobacterial cells can also be dormant and thus completely resistant.](https://reader035.fdocuments.us/reader035/viewer/2022062216/56649d9c5503460f94a8515d/html5/thumbnails/7.jpg)
Isoniazid The most active drug for the treatment of TB (1952), a small (MW 137) simple molecule freely soluble
in water Bactericidal; active-intracellular and extracellular
organisms Less effective in atypical mycobacteria MOA: inhibits synthesis of mycolic acid Availability: 50, 100, 300mg tab; 100-200mg/5ml susp.
![Page 8: I. Slowly growing organism; making them relatively resistant to antibiotics II. Mycobacterial cells can also be dormant and thus completely resistant.](https://reader035.fdocuments.us/reader035/viewer/2022062216/56649d9c5503460f94a8515d/html5/thumbnails/8.jpg)
Resistance - due to mutations:
a. inhA
b. katG
c. ahpC
d. kasA
- if used as a single drug, 10-20% prevalence Kinetics: readily absorbed in the GIT; serum conc. 3-
5ug/ml in 1-2 hrs.; acetylation by liver N-acetyltransferase (rapid acetylators vs. slow acetylators); urine
![Page 9: I. Slowly growing organism; making them relatively resistant to antibiotics II. Mycobacterial cells can also be dormant and thus completely resistant.](https://reader035.fdocuments.us/reader035/viewer/2022062216/56649d9c5503460f94a8515d/html5/thumbnails/9.jpg)
Dynamics: dose: 5mgkd (child) or 300mgd (adult) daily 15mgkd or 900mg in twice weekly dosing + rifampin 600mg - add Pyridoxine 25-50mgd if (+) neuropathy - as a single agent in cases of: a. recent converters b. immunocompromised individuals c. close contacts d. abnormal CXR but activity has been R/O 300mgd or 900mg twice weekly x 6 mos.
![Page 10: I. Slowly growing organism; making them relatively resistant to antibiotics II. Mycobacterial cells can also be dormant and thus completely resistant.](https://reader035.fdocuments.us/reader035/viewer/2022062216/56649d9c5503460f94a8515d/html5/thumbnails/10.jpg)
Adverse effects:
a. allergic reactions – fever, rashes, drug-induced SLE
b. hepatitis – major toxic effect; age-dependent; 10-20% asymptomatic; if with clinical hepatitis, D/C INH; acetylhydrazide
c. peripheral neuropathy – seen in 10-20% being given >5mgkd
d. misc. reactions – hematologic abnormality, GI discomfort
Drug interaction: phenytoin, AlOH
![Page 11: I. Slowly growing organism; making them relatively resistant to antibiotics II. Mycobacterial cells can also be dormant and thus completely resistant.](https://reader035.fdocuments.us/reader035/viewer/2022062216/56649d9c5503460f94a8515d/html5/thumbnails/11.jpg)
Rifampin
A large (MW 823) complex semisynthetic derivative of Rifamycin ( Streptomyces mediterranei)
Active against gm (+), gm(-) cocci, some enteric bacteria, chlamydia
Cross resistance with Rifabutin Bactericidal; penetrates intracellularly MOA: binds with the β-subunit of bacterial DNA dependent
RNA polymerase → inhibit RNA synthesis
![Page 12: I. Slowly growing organism; making them relatively resistant to antibiotics II. Mycobacterial cells can also be dormant and thus completely resistant.](https://reader035.fdocuments.us/reader035/viewer/2022062216/56649d9c5503460f94a8515d/html5/thumbnails/12.jpg)
Resistance: mutations in rpoβ Kinetics: well absorbed; highly protein-bound (↑ in CSF in
meningeal inflammation); excreted in bile, feces, urine; undergoes enterohepatic recirculation
Clinical uses:
a. mycobacterial infection
600mgd (10mgkd) + INH, Ethambutol x 6 mos.
atypical mycobacteria 600mgd or 2x weekly
x 6 mos.
leprosy 600mgd or 2x weekly x 6 mos.
+ sulfone
![Page 13: I. Slowly growing organism; making them relatively resistant to antibiotics II. Mycobacterial cells can also be dormant and thus completely resistant.](https://reader035.fdocuments.us/reader035/viewer/2022062216/56649d9c5503460f94a8515d/html5/thumbnails/13.jpg)
b. other indications:
meningococcal carriage 600mgd x 2 days H. influenzae typeB contact – 20mgkd x 4 days staph. - + another agent pneumococci (meningitis) - + ceftriaxone or vancomycin Adverse effect: a. orange color urine, sweat, tears, contact lens b. cholestatic jaundice c. flu-like syndrome – if given < 2x weekly d. hepatitis – occ. Drug interaction: microsomal enzyme inducer
(methadone, anticoagulant, protease inhibitor, some anticonvulsant, ketoconazole, contraceptive, cyclosporine, chloramphenicol)
![Page 14: I. Slowly growing organism; making them relatively resistant to antibiotics II. Mycobacterial cells can also be dormant and thus completely resistant.](https://reader035.fdocuments.us/reader035/viewer/2022062216/56649d9c5503460f94a8515d/html5/thumbnails/14.jpg)
Ethambutol Synthetic, water-soluble, heat stable compound MOA: inhibitor of mycobacterial arabinosyl
transferase (involved in the polymeration of arabino- glycan, an essential component of mycobacterial cell wall barrier) by embCAB operon
Resistance: mutations within the embB structural gene or overexpression of emb gene products
Kinetics: well wbsorbed; CSF conc. –variable (4-69% in inflammed meninges); excreted 20% feces, 50% urine (reduced dose by half if with renal failure)
![Page 15: I. Slowly growing organism; making them relatively resistant to antibiotics II. Mycobacterial cells can also be dormant and thus completely resistant.](https://reader035.fdocuments.us/reader035/viewer/2022062216/56649d9c5503460f94a8515d/html5/thumbnails/15.jpg)
Dose: 15-25 mgkd + INH + Rifampin
50mgkg twice weekly dosing Adverse effect:
retrobulbar neuritis – most common; loss of
visual acuity and red-green color blindness);
dose-related (25mgkd)
hyperuricemia C/I: very young children because visual acuity
assessment is difficult
![Page 16: I. Slowly growing organism; making them relatively resistant to antibiotics II. Mycobacterial cells can also be dormant and thus completely resistant.](https://reader035.fdocuments.us/reader035/viewer/2022062216/56649d9c5503460f94a8515d/html5/thumbnails/16.jpg)
Pyrazinamide A relative of nicotinamide, stable, inexpensive Inhibits intracellular organism MOA: inhibits mycobacterial fatty acid synthase I involved in mycolic
acid synthesis Resistance: mutations in pncA Kinetics: well absorbed; distributed widely, in inflammed meninges;
t1/2 8-11 hrs. Clinical use:
a. 25mgkd + INH + Rifampin x 6 mos. or
50-70mgkg 2x-3x weekly dosing
b. multi-drug resistant cases
PZA + Ciprofloxacin or Ofloxacin
-prevention of active disease in close
contacts and recent converters
![Page 17: I. Slowly growing organism; making them relatively resistant to antibiotics II. Mycobacterial cells can also be dormant and thus completely resistant.](https://reader035.fdocuments.us/reader035/viewer/2022062216/56649d9c5503460f94a8515d/html5/thumbnails/17.jpg)
Adverse effects: a. hepatotoxicity (1-5%) b. nausea, vomiting c. drug fever d. hyperuricemia (gouty arthritis)
![Page 18: I. Slowly growing organism; making them relatively resistant to antibiotics II. Mycobacterial cells can also be dormant and thus completely resistant.](https://reader035.fdocuments.us/reader035/viewer/2022062216/56649d9c5503460f94a8515d/html5/thumbnails/18.jpg)
Streptomycin Resistant to some non-tuberculous species Extracellular tubercle bacilli; inflammed
meninges MOA: interfere with protein synthesis (30s
subunit) Resistance: point mutation in rpsL gene or rrs
that alters the ribosomal binding site Clinical use: a. severe, life threatening forms of TB b. drug resistance Dose: 15mgkd IM or IV x several weeks ffed. by
1-1.5gm. 2-3x weekly x 6 mos. Adverse reaction: ototoxicity, nephrotoxicity
![Page 19: I. Slowly growing organism; making them relatively resistant to antibiotics II. Mycobacterial cells can also be dormant and thus completely resistant.](https://reader035.fdocuments.us/reader035/viewer/2022062216/56649d9c5503460f94a8515d/html5/thumbnails/19.jpg)
![Page 20: I. Slowly growing organism; making them relatively resistant to antibiotics II. Mycobacterial cells can also be dormant and thus completely resistant.](https://reader035.fdocuments.us/reader035/viewer/2022062216/56649d9c5503460f94a8515d/html5/thumbnails/20.jpg)
![Page 21: I. Slowly growing organism; making them relatively resistant to antibiotics II. Mycobacterial cells can also be dormant and thus completely resistant.](https://reader035.fdocuments.us/reader035/viewer/2022062216/56649d9c5503460f94a8515d/html5/thumbnails/21.jpg)
![Page 22: I. Slowly growing organism; making them relatively resistant to antibiotics II. Mycobacterial cells can also be dormant and thus completely resistant.](https://reader035.fdocuments.us/reader035/viewer/2022062216/56649d9c5503460f94a8515d/html5/thumbnails/22.jpg)
![Page 23: I. Slowly growing organism; making them relatively resistant to antibiotics II. Mycobacterial cells can also be dormant and thus completely resistant.](https://reader035.fdocuments.us/reader035/viewer/2022062216/56649d9c5503460f94a8515d/html5/thumbnails/23.jpg)
Alternative or Second Line Drugs
![Page 24: I. Slowly growing organism; making them relatively resistant to antibiotics II. Mycobacterial cells can also be dormant and thus completely resistant.](https://reader035.fdocuments.us/reader035/viewer/2022062216/56649d9c5503460f94a8515d/html5/thumbnails/24.jpg)
•Uses: a. resistance b. failure of clinical response to conventional tx. c. toxic effects
Ethionamide Related to INH; poorly soluble in water; liver MOA: blocks mycolic acid synthesis Dose: 1 gm/d – to achieve serum concentration of 20
ug/ml; CSF conc.; causes gastric irritation and neurologic symptom
Adverse effect: hepatotoxic; neurotoxicity Dose: 250 mg OD → 500-750 mg OD Resistance: when used as single agent
![Page 25: I. Slowly growing organism; making them relatively resistant to antibiotics II. Mycobacterial cells can also be dormant and thus completely resistant.](https://reader035.fdocuments.us/reader035/viewer/2022062216/56649d9c5503460f94a8515d/html5/thumbnails/25.jpg)
Capreomycin
MOA: peptide protein synthesis inhibitor from Streptomyces capreolus
Used for multidrug resistant cases (streptomycin, amikacin)
Dose: 1 gm/d IM Resistance: rrs mutation Adverse effect: nephrotoxic, ototoxic
- reduced if 1 gm is given 2-3x weekly after initial response is observed
![Page 26: I. Slowly growing organism; making them relatively resistant to antibiotics II. Mycobacterial cells can also be dormant and thus completely resistant.](https://reader035.fdocuments.us/reader035/viewer/2022062216/56649d9c5503460f94a8515d/html5/thumbnails/26.jpg)
Cycloserine
MOA: inhibitor of cell wall synthesis Dose: 0.5-1gm/d in 2 divided doses Renal excretion (dose is reduced if creatinine clearance
is <50ml/min Adverse effect:
a. peripheral neuropathy (seen in 1st
2 weeks of therapy)
b. CNS dysfunction – depression, psychotic
reactions (pyridoxine 150mg/d is given
to ameliorate neurologic toxicity)
![Page 27: I. Slowly growing organism; making them relatively resistant to antibiotics II. Mycobacterial cells can also be dormant and thus completely resistant.](https://reader035.fdocuments.us/reader035/viewer/2022062216/56649d9c5503460f94a8515d/html5/thumbnails/27.jpg)
Aminosalicylic Acid (PAS)
MOA: folate synthesis antagonist Structure – similar to PABA and sulfonamides Widely distributed in tissues and body fluids except in
CSF; excreted in urine Adverse effect: a. anorexia, nausea, lbm, epigastric pain b. peptic ulceration, hgge c. hypersensitivity reaction – fever, jt. pains, skin rashes, hepatosplenomegaly, hepatitis, adenopathy, granulocytopenia →seen 3-8 weeks of PAS
![Page 28: I. Slowly growing organism; making them relatively resistant to antibiotics II. Mycobacterial cells can also be dormant and thus completely resistant.](https://reader035.fdocuments.us/reader035/viewer/2022062216/56649d9c5503460f94a8515d/html5/thumbnails/28.jpg)
Kanamycin and Amikacin
MOA: inhibits 30s ribosomal subunit For streptomycin resistant cases, multidrug resistant TB,
atypical mycobacterium Dose: 15 mgkd IV, IM + 1,2 or 3 other drugs x
2 mos. then 1-1.5 gm 2-3x weekly x 4 mos.
![Page 29: I. Slowly growing organism; making them relatively resistant to antibiotics II. Mycobacterial cells can also be dormant and thus completely resistant.](https://reader035.fdocuments.us/reader035/viewer/2022062216/56649d9c5503460f94a8515d/html5/thumbnails/29.jpg)
Ciprofloxacin and Levofloxacin
MOA: inhibits gyrase mediated DNA-supercoiling M. tuberculosis: levofloxacin > ciprofloxacin Atypical mycobacterium: levofloxacin < ciprofloxacin Dose: ciprofloxacin – 750 mg po BID/
levofloxacin – 500 mg po OD
+
2 or more active drugs Prophylaxis: fluoroquinolone + PZA
(multidrug resistant cases) Resistance: mutations in gyrase A subunit
![Page 30: I. Slowly growing organism; making them relatively resistant to antibiotics II. Mycobacterial cells can also be dormant and thus completely resistant.](https://reader035.fdocuments.us/reader035/viewer/2022062216/56649d9c5503460f94a8515d/html5/thumbnails/30.jpg)
Rifabutin
Derived from rifamycin, related to rifampin Uses: a. M. tb, M. avium intracellulare, M. foruitum b. disseminated atypical disease in AIDS pts. with CD4 count of <50/ml. c. prophylaxis: TB x 6 mos. alone or with PZA x 2 mos. Resistance: rpo mutation Less potent inducer – for HIV infected patients receiving other
meds Dose: 300 mg/d if with protease inhibitor – 150 mg/d if with efavirenz – 450 mg/d
![Page 31: I. Slowly growing organism; making them relatively resistant to antibiotics II. Mycobacterial cells can also be dormant and thus completely resistant.](https://reader035.fdocuments.us/reader035/viewer/2022062216/56649d9c5503460f94a8515d/html5/thumbnails/31.jpg)
Rifapentine
Analog of rifampin; against M. tb, M. avium MOA: bacterial RNA polymerase inhibitor Potent inducer of cytochrome p450 Toxicity: Dose: 600 mg once or 2x weekly
![Page 32: I. Slowly growing organism; making them relatively resistant to antibiotics II. Mycobacterial cells can also be dormant and thus completely resistant.](https://reader035.fdocuments.us/reader035/viewer/2022062216/56649d9c5503460f94a8515d/html5/thumbnails/32.jpg)
Clofazimine
Last resort for multidrug resistant TB Effective against leprosy MOA: unknown ( involved in DNA binding) Adverse effect: skin discoloration, GIT intolerance Dose: 200 mg po as single or divided doses
(t1/2 2 mos.- slowly released)
![Page 33: I. Slowly growing organism; making them relatively resistant to antibiotics II. Mycobacterial cells can also be dormant and thus completely resistant.](https://reader035.fdocuments.us/reader035/viewer/2022062216/56649d9c5503460f94a8515d/html5/thumbnails/33.jpg)
Atypical Mycobacteria Not communicable from person to person Disease produced are less severe than TB MAC – disseminated disease in late stages of AIDS;
incurable - 1st line tx: azithromycin 500 mg OD or clarithromycin
500 mg BID + ethambutol 15 mgkd or Clofazimine or Ciprofloxacin 750mg BID or Amikacin
- 2nd line tx: Rifabutin 300 mg OD; Rifampicin; Ethionamide; Cycloserine; Imipenem
- prophylaxis in AIDS pts.: Rifabutin 300 mg OD
![Page 34: I. Slowly growing organism; making them relatively resistant to antibiotics II. Mycobacterial cells can also be dormant and thus completely resistant.](https://reader035.fdocuments.us/reader035/viewer/2022062216/56649d9c5503460f94a8515d/html5/thumbnails/34.jpg)
Mycobacterium marinarum
- skin infections
- 1st line tx: Rifampicin + Ethambutol
- 2nd line tx: TMP-SMX; Clarithromycin; Amikacin; Kanamycin; Minocycline; Doxycycline
![Page 35: I. Slowly growing organism; making them relatively resistant to antibiotics II. Mycobacterial cells can also be dormant and thus completely resistant.](https://reader035.fdocuments.us/reader035/viewer/2022062216/56649d9c5503460f94a8515d/html5/thumbnails/35.jpg)
Mycobacterium scrofulaceum - cervical lymphadenitis - tx: surgical excision
Mycobacterium fortuitum - chronic lung disease and skin/soft tissue
infection - 1st line tx: Amikacin + Doxycycline - 2nd line tx: Cefoxitin; Rifampicin; TMP-SMX;
Ciprofloxacin; Ofloxacin; Imipenem; Clarithromycin
![Page 36: I. Slowly growing organism; making them relatively resistant to antibiotics II. Mycobacterial cells can also be dormant and thus completely resistant.](https://reader035.fdocuments.us/reader035/viewer/2022062216/56649d9c5503460f94a8515d/html5/thumbnails/36.jpg)
Mycobacterium kansasii
- similar to TB but milder
- 1st line tx: INH + Rifampicin + Ethambutol
- 2nd line tx: Ethionamide; Cycloserine; Clarithromycin; Amikacin; Streptomycin
![Page 37: I. Slowly growing organism; making them relatively resistant to antibiotics II. Mycobacterial cells can also be dormant and thus completely resistant.](https://reader035.fdocuments.us/reader035/viewer/2022062216/56649d9c5503460f94a8515d/html5/thumbnails/37.jpg)
Leprosy
Caused by M. lepraeTropical, warm temperate regionsSkin and nerve predilectionDepends upon cell-mediated immunityDx: biopsy; slit skin smearsMode of transmission: nasal secretions
![Page 38: I. Slowly growing organism; making them relatively resistant to antibiotics II. Mycobacterial cells can also be dormant and thus completely resistant.](https://reader035.fdocuments.us/reader035/viewer/2022062216/56649d9c5503460f94a8515d/html5/thumbnails/38.jpg)
Clinical types of Leprosy:
1. Tuberculoid leprosy – skin macules with clear centers and well defined margins; anesthetic; no Virchow cells; (+) lepromin test
2. Borderline tuberculoid3. Borderline disease4. Borderline lepromatous5. Lepromatous – impaired cell immunity;
atrophy of skin, muscles; amputations; spontaneous ulcerations
![Page 39: I. Slowly growing organism; making them relatively resistant to antibiotics II. Mycobacterial cells can also be dormant and thus completely resistant.](https://reader035.fdocuments.us/reader035/viewer/2022062216/56649d9c5503460f94a8515d/html5/thumbnails/39.jpg)
Leprosy
Dapsone (diaminodiphenylsulfone) MOA: inhibits folate synthesis Uses: a. leprosy
b. prevent and treat P. carinii in AIDS Mgt: dapsone + rifampin + clofazimine (100mg OD) (600mg monthly) (100mg/d po)
Adverse effect: hemolysis, GIT intolerance, erythema nodosum leprosum (steroids/thalidomide)
![Page 40: I. Slowly growing organism; making them relatively resistant to antibiotics II. Mycobacterial cells can also be dormant and thus completely resistant.](https://reader035.fdocuments.us/reader035/viewer/2022062216/56649d9c5503460f94a8515d/html5/thumbnails/40.jpg)
Jarisch-Herxheimer reaction:
- exacerbation of lepromatous leprosy
- is induced 5-6 wks. after initiation of treatment
- fever, malaise, exfoliative dermatitis, jaundice with hepatic necrosis, lymphadenopathy, methemoglobinemia, anemia
![Page 41: I. Slowly growing organism; making them relatively resistant to antibiotics II. Mycobacterial cells can also be dormant and thus completely resistant.](https://reader035.fdocuments.us/reader035/viewer/2022062216/56649d9c5503460f94a8515d/html5/thumbnails/41.jpg)
Leprosy (cont.)
Rifampicin – 600mg OD or once a monthClofazimine (Lamprene) MOA: inhibit the template function of DNA
by binding to it -prevents the development of erythema
nodosum leprosum - oral; 100mg OD - SE: discoloration of the skin, eosinophilic
enteritis
![Page 42: I. Slowly growing organism; making them relatively resistant to antibiotics II. Mycobacterial cells can also be dormant and thus completely resistant.](https://reader035.fdocuments.us/reader035/viewer/2022062216/56649d9c5503460f94a8515d/html5/thumbnails/42.jpg)
Miscellaneous agents for leprosy
Thalidomide – treatment of erythema nodosum leprosum
-dose: 100 – 300mg/day; teratogenicEthionamide – a substitute for clofazimine
-dose: 250 -375mg/day
![Page 43: I. Slowly growing organism; making them relatively resistant to antibiotics II. Mycobacterial cells can also be dormant and thus completely resistant.](https://reader035.fdocuments.us/reader035/viewer/2022062216/56649d9c5503460f94a8515d/html5/thumbnails/43.jpg)
Management of Leprosy Tuberculoid, borderline tuberculoid and
indeterminate disease:
Dapsone 100 mg daily +
Rifampicin 600 mg daily/monthly
X 6 mos. Lepromatous, borderline lepromatous,
borderline disease:
Dapsone 100 mg daily +
Rifampicin 60 mg daily/monthly +/-
Clofazimine 100 mg daily X 1–5 yrs.
![Page 44: I. Slowly growing organism; making them relatively resistant to antibiotics II. Mycobacterial cells can also be dormant and thus completely resistant.](https://reader035.fdocuments.us/reader035/viewer/2022062216/56649d9c5503460f94a8515d/html5/thumbnails/44.jpg)
![Page 45: I. Slowly growing organism; making them relatively resistant to antibiotics II. Mycobacterial cells can also be dormant and thus completely resistant.](https://reader035.fdocuments.us/reader035/viewer/2022062216/56649d9c5503460f94a8515d/html5/thumbnails/45.jpg)
Leprosy-Classic Facial Appearance: Patient with chronic M Leprae infection that has led to collapse of nasal structure and subsequent development of classic "Leonine Facies.“
Skin discoloration is due to medication used to treat this infection. Patient has lost digits of hand secondary to leprosy as well.
![Page 46: I. Slowly growing organism; making them relatively resistant to antibiotics II. Mycobacterial cells can also be dormant and thus completely resistant.](https://reader035.fdocuments.us/reader035/viewer/2022062216/56649d9c5503460f94a8515d/html5/thumbnails/46.jpg)
![Page 47: I. Slowly growing organism; making them relatively resistant to antibiotics II. Mycobacterial cells can also be dormant and thus completely resistant.](https://reader035.fdocuments.us/reader035/viewer/2022062216/56649d9c5503460f94a8515d/html5/thumbnails/47.jpg)
Thank you
Ma. Victoria M. Villarica, M.D.